Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Efficacy of NK510 to Treat NSCLC — Stella

Home/NSCLC/Safety and Efficacy of NK510 to Treat NSCLC

View on ClinicalTrials.gov

Recruiting

Back to NSCLC trials

Safety and Efficacy of NK510 to Treat NSCLC

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Jinling hospital, affiliated to Medical school Nanjing University, Nanjing, Jiangsu

Key details

Phase

Very early testing

Sponsor

Base Therapeutics (Shanghai) Co., Ltd.

Collaborators

Jinling Hospital, China

Enrollment target

~12 participants

Started

July 2023

Primary completion

July 2026

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.